CONMED and Climb Bio receive divergent analyst ratings

CONMED Corporation (NYSE:CNMD) earned an average rating of “Reduce” from eight analysts, with three sell and five hold recommendations and an average 12‑month price target of $38.80. Recent analyst notes include Bank of America’s underperform rating with a $40 target, Needham’s hold stance, Weiss’s sell rating, Zacks’ strong‑sell downgrade and Wall Street Zen’s upgrade to buy. The stock opened at $42.73, and the company reported Q4 earnings of $0.89 per share, beating the $0.82 consensus, on revenue of $317.05 million, a 4% net margin and a 13.84% return on equity.

Climb Bio, Inc. (NASDAQ:CLYM) saw its shares jump 10.9% after Wedbush raised its price target to $20 and retained an outperform rating. The stock traded near $14.25. Other analyst actions include HC Wainwright’s buy rating with a $20 target, Weiss’s sell rating, Chardan’s buy at $22, Wall Street Zen’s hold upgrade, and BTIG’s buy rating with a $20 target. The consensus rating is now “Buy” with an average target of $22. Hedge funds such as Peapod Lane Capital, XTX Topco, Virtu Financial, Blair William & Co., and HSBC Holdings have recently increased their stakes in the company.